

# The Pharma Legal Handbook

---

# Slovakia

Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs · Orphan Drugs and Rare Diseases · Localization · Biosimilars and Biologics

# Slovakia

The Pharma Legal Handbook answers essential questions about this environment for pharmaceuticals in Slovakia. It is a must have for any company operating in the country or looking to enter the market.

Prepared in association with PRK Partners, a leading regional-full-service law firm, it should answer any questions linked to Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks and Patents.

PharmaBoardroom is not responsible for any mistakes contained within this publication. For specific advice on any legal issue, please contact a qualified professional.

Copyright: All rights reserved. No part of this publication may be reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

\* THIS REPORT WAS ORIGINALLY PUBLISHED IN MAY 2019 AND THE INFORMATION CONTAINED WITHIN IS SUBJECT TO CHANGE.

\*\*LAST UPDATE: DECEMBER 2025

## P / R / K

ATTORNEYS AT LAW

PRK Partners is a leading full-service law firm with a team of experienced legal and tax professionals. In its over 30 years of outstanding service, PRK has worked on many of the region's largest and most complex transactions. With offices and teams in both Slovakia and the Czech Republic, PRK is perfectly suited for handling cross-border matters between these two countries. PRK combines profound knowledge of the local legal system with an international perspective.

The Life Sciences practice at PRK Partners advises leading pharmaceutical, biotechnology, medical device, food, cosmetics and tobacco firms navigate the complex national and EU regulatory landscape.

The team advises on a broad spectrum of legal issues from establishment or start-up firms in life sciences and healthcare, R&D to manufacturing, marketing, distribution and sale, pricing and reimbursement of drugs, biologics and medical devices, IP legal issues, data protection, compliance, enforcement, litigation, transactions, public procurement, antitrust and competition issues.

The firm has garnered significant international and national awards and has a strong commitment to corporate social responsibility and pro bono work. The firm has been long-term ranked by international ranking agencies of law firms such as Chambers and Partners, TheLegal500 or IFLR1000.

PRK Partners is the exclusive member law firm in the Czech Republic for Lex Mundi, the world's leading network of independent law firms, with in-depth experience in 100+ countries worldwide. The firm is also a member of AFI, LMA, CVCA, ITECHLAW, INTA and Energy Law Group.



# THE AUTHORS

---



**JUDR. ING.  
MIRIAM  
GALANDOVA  
LL.M., FCCA**

---

**Partner, PRK Partners Bratislava**

e-mail: [miriam.galandova@prkpartners.com](mailto:miriam.galandova@prkpartners.com)  
tel: +421 232 333 232

JUDr. Ing. Miriam Galandova LL.M., FCCA obtained an JUDr. Ing LL.M. degree from the University of London in International Arbitration and Commercial Law, a Doctorate (JUDr.) from the Faculty of Law of Comenius University in Bratislava and a Master's degree (Ing.) from the Faculty of Commerce of the University of Economics in Bratislava. She worked for six years in the Bratislava office of Arthur Andersen and then for eight years at White & Case in Bratislava, where she was named a partner in 2009.

With her qualification in both economic and legal areas she is able to provide top legal services in all her assignments requiring complex legal and economic analyses. By working for local and international corporate clients Miriam gained experience in the areas of pharmaceutical law and food-processing industries, tax law, corporate law and dispute resolution, including representing clients in arbitration and court proceedings. She regularly advises clients from a variety of regulated industries, including the pharmaceutical companies and other entities of the health, life sciences and food-processing sectors. She provides broad scale of advice from legal and tax assistance in the field of corporate and regulatory matter, pricing, advertising and promotional matters to licencing procedures for healthcare service providers.

Miriam was a member of the recodification committee responsible for preparing the new Slovak Civil Code. She is President of the Slovak Chamber of Tax Advisors, where she is also a member of the Methodical Legislative Committee for Corporate Income Tax and the Methodical Legislative Committee for International Taxation. Miriam is a member of the Committee for Civil Law at the American Chamber of Commerce in Slovakia. She is an attorney at law admitted to the Slovak Bar Association and a member of the Association of Chartered Certified Accountants (ACCA). Miriam represents the Chamber of Tax Advisors for the Fiscal Committee of the Confederation Fiscale Européenne (CFE). She has recently been appointed as the Chairman of the CFE's Transfer Pricing Group. Miriam has been recommended as a leading practitioner in the areas of corporate and M&A law, dispute resolution and tax law by the respected legal directories Chambers Europe and Chambers Global.



**MGR. JÁN  
LANČARIČ**

---

**Associate, PRK Partners Bratislava**

e-mail: [jan.lacaric@prkpartners.com](mailto:jan.lacaric@prkpartners.com)  
tel: +421 232 333 232

MGR. Ján Lančarič is an attorney at PRK Partners specializing primarily in pharmaceutical law, corporate law, commercial law and competition law (concentrations, agreements restricting competition and abuse of dominance), mergers and acquisitions and litigation.

Ján obtained his Master's degree in Law from the Faculty of Law of the University of Trnava in 2020. He started working at PRK Partners in 2018 as a paralegal and after completing his Master's degree, he had been working at PRK Partners as an Associate. Since 2024, when he was admitted to the Slovak Bar Association Ján is an attorney in PRK Partners.

During his practice, Ján advised Slovak and international clients in a variety of industries mainly in the areas of corporate, competition and M&A law. Ján provides assistance to clients in connection with the establishment of their branches in the Slovak Republic, as well as legal guidance focused on corporate and commercial law matters with respect to the operation of those branches and helps them with regulatory and licencing matters from various sectors, including food, drugs and medical devices sectors. In the area of mergers and acquisitions, Ján participated in the legal audits of a number of Slovak corporations and in the preparation of related transaction documents.

Ján also regularly represents clients before courts in commercial and civil disputes.

P / R / K

ATTORNEYS AT LAW

Bratislava / Prague / Ostrava



**BEST LAW FIRM OF THE YEAR 2025**  
**CORPORATE LAW**

THANK YOU.

# CONTENTS

---

<b>01</b>	<b>REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW</b>	Page 6
<b>02</b>	<b>PRECLINICAL AND CLINICAL TRIAL REQUIREMENTS</b>	Page 16
<b>03</b>	<b>MARKETING, MANUFACTURING, PACKAGING AND LABELING, ADVERTISING</b>	Page 21
<b>04</b>	<b>TRADITIONAL MEDICINES AND OVER-THE-COUNTER PRODUCTS</b>	Page 37
<b>05</b>	<b>PRODUCT LIABILITY</b>	Page 42
<b>06</b>	<b>PATENTS AND TRADEMARKS</b>	Page 48
<b>07</b>	<b>REGULATORY REFORMS</b>	Page 55
<b>08</b>	<b>CANNABINOID DRUGS, MEDICINAL CANNABIS AND OPIOID DRUGS</b>	Page 57
<b>09</b>	<b>ORPHAN DRUGS AND RARE DISEASES</b>	Page 66
<b>10</b>	<b>LOCALIZATION</b>	Page 70
<b>11</b>	<b>BIOSIMILARS AND BIOLOGICS</b>	Page 75

---

# 01

## **REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW**

---

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

---

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

---

3. What are the steps to obtaining authorization to develop, test, and market a product?

---

4. What are the approximate fees for each authorization?

---

5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?

---

6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?

---

7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

8. How is compliance with regulation monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?

---

9. What is the potential range of penalties for noncompliance?

---

10. Is there a national healthcare system? If so, how is it administered and funded?

---

11. How does the government (or public) healthcare system function with private sector healthcare?

---

12. Are prices of drugs and devices regulated and, if so, how?

---

13. How are drugs and devices used by patients paid for? What roles do public and private payers play?

---

14. Who dispenses drugs and devices to patients and how are those dispensers compensated?

---

15. What are the professional and legal responsibilities of those who dispense drugs and devices? What role do they play in providing patient care, information, and safety?

---

# 01 REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

---

## **1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?**

In the Slovak Republic, the main regulatory authorities over medicinal products, biologicals, and medical devices are the State Institute for Drug Control and the Ministry of Health.

## **2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?**

In the Slovak Republic, the main regulatory framework for the authorization of medicinal products, biologicals, and medical devices is the Act on Medicinal Products and related regulations (including respective EU regulations which are directly applicable in the Slovak Republic). As regards the pricing and reimbursement of medicinal products, biologicals, and medical devices, the main regulatory framework is the Act on Reimbursement of Medicinal Products and Medical Devices from the Public Health Insurance System and related regulations.

## **3. What are the steps to obtaining authorization to develop, test, and market a product?**

In the Slovak Republic, the handling with medicinal products and medical devices, in particular the production of medicinal products, wholesale distribution of medicinal products and provision of pharmacy services, requires a special license for the respective activity issued under the Act on Medicinal Products.

The authorization for manufacturing of medicinal products is required for manufacturing of medicinal products. The State Institute for Drug Control recognizes the authorization for manufacturing of medicinal products issued by the respective authority of another EEA member state. The authorization for manufacturing of medicinal products is required also for import of medicinal products from non-EEA countries. If the applicant fulfils the respective obligations specified by the Act on Medicinal Products, the State Institute for Drug Control issues the authorization for manufacturing of medicinal products within 90 days following the delivery of the application.

As of 31 January 2025, the Slovak national clinical trials regulation underwent a significant reform in order to implement the EU Regulation No. 536/2014 on clinical trials. Specifically, the whole general national regulation was replaced by direct application of EU Regulation No. 536/2014 on clinical trials. Consequently, the clinical trials are subject to prior review performed by ethics committee and approval of the reporting member state in accordance with the EU Regulation No. 536/2014 on clinical trials. The sponsor is only allowed to conduct the clinical trial once they received the notification on approval of the clinical trial.

In order to place the medicinal product on the Slovak market, the marketing authorization of the State Institute for Drug Control is required, except for the authorization issued by the European Commission through the centralized procedure which is then valid for all EEA member states. The State Institute for Drug Control has 210 days for reviewing the application following its delivery. Marketing authorization may be also received within the EEA following simplified procedures, i.e. the mutual recognition procedure (recognition of an existing national marketing authorization by one or more EEA member states) or the decentralized procedure (the application for marketing authorization is submitted simultaneously in several EEA member states). Still, a separate authorization issued by the State Institute for Drug Control is required.

Please see [Answer No. 22 of Chapter 3: Marketing, Manufacturing, Packaging & Labeling, Advertising](#) for the details about the process for obtaining the marketing authorization of new medicinal products and other medicinal products in the Slovak Republic and the requirements for placing medical devices into the Slovak market.

---

#### **4. What are the approximate fees for each authorization?**

The administrative fee for the authorization for manufacturing of medicinal products amounts to EUR 100 if the manufacturer is an individual and EUR 250 if the manufacturer is a legal entity.

The administrative fee for the proceedings on the approval of the clinical trial varies from EUR 3,500 to EUR 11,000 with respect to medicinal products and EUR 500 with respect to medical devices.

The administrative fee for the decision on the approval of the clinical trial amounts to EUR 331.50 with respect to medicinal products and EUR 300 with respect to medical devices.

The administrative fees for marketing approval are published at the webpage of the State Institute for Drug Control ([click here](#)).

The price list of the services provided by the State Institute for Drug Control sets prices for additional activities performed by the State Institute for Drug Control, e.g. issuance of a certificate on compliance with the requirements of the GMP, the assessment of the technical documentation in case of the first notification/registration of a medical device/the manufacturer of a medical device.

---

#### **5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?**

Marketing authorization of a medicinal product is valid for five years. The State Institute for Drug Control may prolong the validity of the authorization on the basis of a written application submitted no later than nine months before the expiry date of the authorization, and on the basis of the review of the risk-benefit balance of the medicinal product.

Based on reasonable grounds relating to the supervision of medicinal products (including the exposition of a nonsufficient amount of patient to the medicinal product), the State Institute for Drug Control may decide to extend the marketing authorization of a medicine for additional five years. Otherwise, it will issue a decision to extend the marketing authorization for an unlimited period of time.

**6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?**

A generic version of a medicinal product requires also the marketing authorization issued by the State Institute for Drug Control. In case of generics, the applicant must prove to the State Institute for Drug Control that the product is bioequivalent to the reference medicinal product which has been registered in at least one EEA member state for at least eight years. In addition, the applicant must provide the State Institute for Drug Control with all information and documents as required in the case of authorization procedure of a new medicinal product. However, the applicant does not have to submit to the State Institute for Drug Control the results of the toxicological, pharmacological and clinical testing carried out by the applicant for the generic version, as the applicant can submit the results of these testing already carried out in relation to the reference medicinal product.

In the Slovak Republic, there is basically no difference between local manufacturers and foreign-owned manufacturers. However, the applicants for the marketing authorization must have their residency or registered seat in the Slovak Republic or in another EEA member state. In case of medical devices, the procedure differs if the manufacturer's place of business or registered seat is outside the Slovak Republic (please see **Question 22 of Chapter 3: Marketing, Manufacturing, Packaging & Labeling, Advertising** for more details).

---

**7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?**

There is no specific regulation on the combination products. Basically, combination products drug + drug and drug + biologic fall under the regulatory framework of medicinal products and the Act on Medicinal Products should be applicable.

With respect to the combination products drug + device, biologic + device and drug + biologic + device, if the medical device and the medicinal products (the active substance) form an integral product, the medical device is intended only for use in such combination, is not reusable, and fulfils the technical requirements of the safety and effectiveness as specified by specific legal regulations, it shall be tested and approved as a medicinal product. Further, when deciding whether a product is a medicinal product or a medical device, the main effect shall be considered. Also, when deciding whether a product is a medicinal product or a medical device, the main effect shall be considered with respect to the medicinal product, and the main mechanism of the effect by which the purpose of determining specified by the manufacturer is achieved shall be considered with respect to the medical device. In addition, the EU Medical Devices Regulation (2017/745) which regulates also these matters fully applies in the Slovak Republic from 26 May 2021.

---

**8. How is compliance with**